Accéder au contenu
Merck
Toutes les photos(1)

Documents

36147

Supelco

Mecoprop

PESTANAL®, analytical standard

Synonyme(s) :

2-(4-Chloro-2-methylphenoxy)propionic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H11ClO3
Numéro CAS:
93-65-2
Poids moléculaire :
214.65
Numéro Beilstein :
6568283
Numéro CE :
202-264-4
Numéro MDL:
MFCD00002648
Code UNSPSC :
41116107
ID de substance PubChem :
329755294
Nomenclature NACRES :
NA.24

Qualité

analytical standard

Niveau de qualité

100

Gamme de produits

PESTANAL®

Durée de conservation

limited shelf life, expiry date on the label

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Application(s)

agriculture
environmental

Format

neat

Chaîne SMILES 

CC(Oc1ccc(Cl)cc1C)C(O)=O

InChI

1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)

Clé InChI

WNTGYJSOUMFZEP-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Informations légales

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

Skull and crossbonesCorrosionEnvironment
GHS06,GHS05,GHS09

Mention d'avertissement

Danger

Mentions de danger

H302,H311,H315,H318,H410

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1 - Skin Irrit. 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number
BCCK2521
BCCB1112
BCBV9245
SZBE010XV
SZB9015XV

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

Novaluron PESTANAL®, analytical standard

Supelco

32419

Novaluron

Ametryn PESTANAL®, analytical standard

Supelco

45321

Ametryn

Diuron PESTANAL®, analytical standard

Supelco

45463

Diuron

Yutaka Osuga et al.
Obstetrics and gynecology, 133(3), 423-433 (2019-02-12)
To investigate the noninferiority of relugolix compared with leuprorelin acetate in reducing heavy menstrual bleeding associated with uterine leiomyomas. In a double-blind, double-dummy trial, premenopausal women with uterine leiomyomas and heavy menstrual bleeding defined as a pictorial blood loss assessment
Régis Peffault de Latour et al.
British journal of haematology, 191(3), 476-485 (2020-05-26)
Ravulizumab, a novel long-acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non-inferior to eculizumab for all efficacy outcomes in two randomised, open-label, phase 3 trials in C5 inhibitor-naïve (Study 301) and eculizumab-experienced (Study 302) adult patients
Kohei Shitara et al.
Oncotarget, 8(45), 79546-79555 (2017-11-08)
SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and
Pablo J Maid et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 24(4), 177-182 (2017-12-13)
Biologic agents may induce immune responses that could impact drug action. The aims of this study were to assess antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit
Kathleen Clifford et al.
Clinical journal of oncology nursing, 22(4), E103-E114 (2018-07-24)
Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-expressing cells. This article assesses the occurrence and management of the most frequent and clinically relevant BV-associated adverse events (AEs), with a focus on Hodgkin lymphoma and systemic anaplastic large cell
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique